The financing will go toward efforts by the German firm to bring its point-of-care screening system for drug-resistant bacteria to hospitals.
The firm, which raised $7.1 million from its IPO last week, is looking to move into geographies where a need for infectious disease tests are already well established, its CEO said.
A UK-led international consortium is sequencing tuberculosis genomes and cataloguing drug resistance mutations to enable more rapid NGS-based diagnostics.
Among the tests that French national health insurance system will reimburse are IGRA tests, including ones from Qiagen and Oxford Immunotec, for screening TB.
QuantiFeron-TB Gold Plus is an immunoassay that detects the release of interferon-gamma as a proxy for latent tuberculosis infection.
The company's tuberculosis business rose 8 percent, and its newly acquired tick-borne disease franchise notched $3.0 million in revenues during the quarter.
Quanterix's Simoa single-molecule detection method combined with high-affinity antibodies detected minute levels of problematic interferon alpha proteins, a study said.
The Alabama-based firm has grown its infectious disease testing menu for the BD Max system to six CE-marked tests identifying bacteria, viruses, or fungi.
The collaborating researchers aim to develop a test kit that uses a minimum amount of electricity, and can still send information from some of the most remote regions of the world.
The company has also developed software that will enable automated melt curve analysis on Cepheid's existing GeneXpert platforms.